Mitoxantrone
- Generic Name
- Mitoxantrone
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28N4O6
- CAS Number
- 65271-80-9
- Unique Ingredient Identifier
- BZ114NVM5P
- Background
An anthracenedione-derived antineoplastic agent.
- Indication
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma
- Associated Therapies
- Autologous hematopoietic stem cell transplant
Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2016-09-26
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 83
- Registration Number
- NCT00416910
Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)
- Conditions
- First Posted Date
- 2006-12-06
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 300
- Registration Number
- NCT00408278
- Locations
- 🇪🇸
Hospital La Fe, Valencia, Spain
🇪🇸Hospital de Cruces, Santander, Spain
🇪🇸Hospital de Santiago de Compostela, Santiago de Compostela, Spain
A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)
- Conditions
- Interventions
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 106
- Registration Number
- NCT00385827
A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease)
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2020-12-28
- Lead Sponsor
- State University of New York at Buffalo
- Target Recruit Count
- 5
- Registration Number
- NCT00304291
- Locations
- 🇺🇸
Baird Multiple Sclerosis Center, Buffalo, New York, United States
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2022-04-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT00290511
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years
- Conditions
- Interventions
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2019-05-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00254410
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2005-12-22
- Lead Sponsor
- Rennes University Hospital
- Target Recruit Count
- 124
- Registration Number
- NCT00219908
- Locations
- 🇫🇷
Centre Guy de Chauliac, Montpellier, France
🇫🇷Pierre Weitheimer Hospital, Lyon, France
🇫🇷Hôpital Cote de Nacre, Caen, France
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 720
- Registration Number
- NCT00199069
- Locations
- 🇩🇪
University Hospital, Medical Dept. II, Frankfurt, Germany
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 51
- Registration Number
- NCT00193479
- Locations
- 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2011-07-11
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 80
- Registration Number
- NCT00180128
- Locations
- 🇩🇪
Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.